ReNeuron Group plc Appointment of Chief Scientific Officer (2106Z)
May 20 2021 - 2:00AM
UK Regulatory
TIDMRENE
RNS Number : 2106Z
ReNeuron Group plc
20 May 2021
ReNeuron Group plc
("ReNeuron" or the "Company")
Appointment of Chief Scientific Officer
ReNeuron Group plc (AIM: RENE), a UK-based global leader in the
development of cell-based therapeutics, announces the appointment
of Dr Stefano Pluchino as Chief Scientific Officer with immediate
effect. Dr Pluchino will join the Company on a part-time basis and
brings with him a wealth of knowledge of cell and gene therapy.
Dr Stefano Pluchino is Reader in Regenerative Neuroimmunology
and Honorary Consultant at the University of Cambridge since 2010.
He obtained his MD and PhD at the University of Siena, Italy, and
progressed to two consecutive post doctorate appointments at the
San Raffaele Scientific Institute in Milan, Italy.
Dr Pluchino has published over 120 peer-reviewed papers,
including several in top journals, including Nature, Cell and Cell
Stem Cell, and is internationally recognised as a leader and
pioneer in the field of regenerative neuroimmunology. He was the
recipient of the 2003 European Charcot Foundation (ECF) Award, the
2006 Serono Foundation Multiple Sclerosis Award, the 2007 Rita
Levi-Montalcini award, hosted by the Italian Foundation for
Multiple Sclerosis, the 2009 Italian Ministry of Health Young
Investigator Award and the 2010 International Royan Award for
outstanding research in Stem Cell Biology and Technology.
Olav Hellebø, Chief Executive Officer, commented: "We are
delighted to welcome Dr Pluchino to ReNeuron. His extensive
experience of cell and gene therapy as well as deep knowledge in
the exosomes field will be invaluable to us in what is an
incredibly exciting and progressive time. Dr Pluchino's work is
widely recognised, and we look forward to working alongside him, as
ReNeuron continues to grow and develop its pipeline."
ENDS
Contacts:
ReNeuron www.reneuron.com/investors
Olav Hellebø, Chief Executive Via Walbrook PR
Officer
Stifel Nicolaus Europe Limited (NOMAD
and Joint Broker)
Ben Maddison, Stewart Wallace +44 (0)20 7710 7600
Allenby Capital Limited (Joint Broker) +44 (0)20 3328 5656
James Reeve/George Payne (Corporate
Finance)
Tim Sohal (Sales & Corporate Broking)
Walbrook PR (Media & Investor Relations) +44 (0)20 7933 8780 or reneuron@walbrookpr.com
+44 (0)7980 541 893 / +44 (0)7407
Paul McManus, Alice Woodings 804 654
About ReNeuron
ReNeuron is a global leader in cell-based therapeutics,
harnessing its unique stem cell technologies to develop 'off the
shelf' stem cell treatments, without the need for immunosuppressive
drugs. The Company's lead cell therapy candidate is in clinical
development for the blindness-causing disease, retinitis
pigmentosa.
ReNeuron is also advancing its proprietary exosome technology
platform as a potential delivery system for drugs that treat
diseases of the brain. The Company also has the ability through its
conditionally immortalised induced pluripotent stem cell (iPSC)
platform to make any tissue cells of choice; in-house programmes
are focused on treatments for blood cancers and diabetes.
ReNeuron's shares are traded on the London AIM market under the
symbol RENE.L. For further information visit www.reneuron.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
MSCDZGMKRLDGMZM
(END) Dow Jones Newswires
May 20, 2021 02:00 ET (06:00 GMT)
Reneuron (LSE:RENE)
Historical Stock Chart
From Apr 2024 to May 2024
Reneuron (LSE:RENE)
Historical Stock Chart
From May 2023 to May 2024